MA47130B1 - Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations - Google Patents

Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations

Info

Publication number
MA47130B1
MA47130B1 MA47130A MA47130A MA47130B1 MA 47130 B1 MA47130 B1 MA 47130B1 MA 47130 A MA47130 A MA 47130A MA 47130 A MA47130 A MA 47130A MA 47130 B1 MA47130 B1 MA 47130B1
Authority
MA
Morocco
Prior art keywords
human
specifically binding
antibodies specifically
antibodies
dysregulation
Prior art date
Application number
MA47130A
Other languages
English (en)
Other versions
MA47130A (fr
Inventor
Matthew Pollard
Anthony Gerard Doyle
David Jose Simon LAINE
Lynn Dorothy Poulton
Adam William Clarke
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Publication of MA47130A publication Critical patent/MA47130A/fr
Publication of MA47130B1 publication Critical patent/MA47130B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)

Abstract

L'invention concerne des anticorps recombinants se liant spécifiquement à IL-5 ainsi qu'un complexe d'IL-15 et le récepteur-alpha de l'IL-15. Les anticorps inhibent la prolifération des cellules immunitaires, et peuvent être utilisés dans le traitement de n'importe quelle maladie ou affection auto-immune ou inflammatoire associée à une dérégulation de l'IL-15, y compris la maladie cœliaque.
MA47130A 2016-12-21 2017-12-21 Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations MA47130B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437143P 2016-12-21 2016-12-21
EP17883800.9A EP3558369B1 (fr) 2016-12-21 2017-12-21 Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations
PCT/US2017/067917 WO2018119246A1 (fr) 2016-12-21 2017-12-21 Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations

Publications (2)

Publication Number Publication Date
MA47130A MA47130A (fr) 2019-10-30
MA47130B1 true MA47130B1 (fr) 2025-05-30

Family

ID=62627610

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47130A MA47130B1 (fr) 2016-12-21 2017-12-21 Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations

Country Status (30)

Country Link
US (2) US11267883B2 (fr)
EP (2) EP4585261A3 (fr)
JP (2) JP7155126B2 (fr)
KR (2) KR102706743B1 (fr)
CN (1) CN110234349B (fr)
AR (1) AR110414A1 (fr)
AU (2) AU2017382850B2 (fr)
BR (1) BR112019012570A8 (fr)
CA (1) CA3046387A1 (fr)
CL (1) CL2019001729A1 (fr)
DK (1) DK3558369T3 (fr)
EA (1) EA201991514A1 (fr)
ES (1) ES3026508T3 (fr)
FI (1) FI3558369T3 (fr)
HR (1) HRP20250482T1 (fr)
HU (1) HUE071878T2 (fr)
IL (1) IL267113B2 (fr)
LT (1) LT3558369T (fr)
MA (1) MA47130B1 (fr)
MD (1) MD3558369T2 (fr)
MX (2) MX2019007357A (fr)
PE (1) PE20191497A1 (fr)
PH (1) PH12019501453A1 (fr)
PL (1) PL3558369T3 (fr)
PT (1) PT3558369T (fr)
RS (1) RS66900B1 (fr)
SI (1) SI3558369T1 (fr)
UA (1) UA126284C2 (fr)
WO (1) WO2018119246A1 (fr)
ZA (1) ZA201903848B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI707038B (zh) 2013-08-05 2020-10-11 美商扭轉生物科技有限公司 重新合成之基因庫
WO2016126882A1 (fr) 2015-02-04 2016-08-11 Twist Bioscience Corporation Procédés et dispositifs pour assemblage de novo d'acide oligonucléique
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
KR20180050411A (ko) 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
WO2018057526A2 (fr) 2016-09-21 2018-03-29 Twist Bioscience Corporation Stockage de données reposant sur un acide nucléique
RS66900B1 (sr) 2016-12-21 2025-07-31 Cephalon Llc Antitela koja se specifično vezuju za humani il-15 i njihova upotreba
CN110892485B (zh) 2017-02-22 2024-03-22 特韦斯特生物科学公司 基于核酸的数据存储
JP7169999B2 (ja) 2017-06-12 2022-11-11 ツイスト バイオサイエンス コーポレーション シームレス核酸アセンブリのための方法
WO2018231864A1 (fr) 2017-06-12 2018-12-20 Twist Bioscience Corporation Méthodes d'assemblage d'acides nucléiques continus
AU2018328847A1 (en) 2017-09-11 2020-04-23 Twist Bioscience Corporation GPCR binding proteins and synthesis thereof
WO2019079769A1 (fr) 2017-10-20 2019-04-25 Twist Bioscience Corporation Nano-puits chauffés pour la synthèse de polynucléotides
EP4715681A2 (fr) 2018-01-04 2026-03-25 Atlas Data Storage, Inc. Stockage d'informations numériques à base d'adn
IL278771B2 (en) 2018-05-18 2025-09-01 Twist Bioscience Corp Polynucleotides, reagents and methods for nucleic acid hybridization
CN112534052B (zh) 2018-07-25 2024-09-20 奥美药业有限公司 全新il-21前药及使用方法
US11828385B2 (en) 2018-12-25 2023-11-28 Ntn Corporation Flow control valve seal and flow control valve device
WO2020139871A1 (fr) 2018-12-26 2020-07-02 Twist Bioscience Corporation Synthèse de novo polynucléotidique hautement précise
AU2020227802A1 (en) 2019-02-26 2021-10-14 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
WO2020176678A1 (fr) 2019-02-26 2020-09-03 Twist Bioscience Corporation Banques de variants d'acides nucléiques pour le récepteur glp1
WO2020252264A1 (fr) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Nouveaux promédicaments d'il-15 et leurs procédés d'utilisation
CA3144644A1 (fr) 2019-06-21 2020-12-24 Twist Bioscience Corporation Assemblage de sequences d'acide nucleique base sur des code-barres
EP4034564A4 (fr) 2019-09-23 2023-12-13 Twist Bioscience Corporation Bibliothèques d'acides nucléiques variants pour des anticorps à domaine unique
US12091777B2 (en) 2019-09-23 2024-09-17 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2
BR112022011235A2 (pt) * 2019-12-09 2022-12-13 Twist Bioscience Corp Bibliotecas de variantes de ácido nucleico para receptores de adenosina
JP7767290B2 (ja) 2020-01-11 2025-11-11 アスクジーン・ファーマ・インコーポレイテッド 新規なマスクされたサイトカインおよびその使用方法
TW202228775A (zh) * 2020-10-14 2022-08-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物及方法
JP2023545821A (ja) * 2020-10-16 2023-10-31 ジェネンテック， インコーポレイテッド 抗ｉＣａｓｐａｓｅ切断基質抗体および使用方法
KR20230147617A (ko) 2021-01-21 2023-10-23 트위스트 바이오사이언스 코포레이션 아데노신 수용체에 관한 방법 및 조성물
CN116655771A (zh) * 2021-05-28 2023-08-29 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
CN119698301A (zh) 2022-08-04 2025-03-25 诺华医药股份公司 Il-15抑制剂用于治疗特应性皮炎
CN118894934A (zh) * 2023-05-05 2024-11-05 北京智仁美博生物科技有限公司 抗人il-15的抗体及其用途
CN117209605B (zh) * 2023-11-09 2024-01-30 北京百普赛斯生物科技股份有限公司 特异性结合il-15的抗体及其应用
WO2025227052A1 (fr) * 2024-04-26 2025-10-30 Cephalon Llc Doses et formulations d'anticorps anti-il-15 pour le traitement de maladies immunitaires

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US7132510B2 (en) * 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
IL160358A0 (en) * 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ATE472556T1 (de) 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
JP4892335B2 (ja) * 2003-02-26 2012-03-07 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
WO2006017853A2 (fr) * 2004-08-11 2006-02-16 Beth Israel Deaconess Medical Center, Inc. Composition contenant une interleukine-15 mutante et suppression de la reponse immunitaire
AU2006216291B2 (en) 2005-02-27 2011-01-27 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2688834C (fr) 2007-06-01 2020-01-07 Ronald Buelow Compositions et procedes pour inhiber des genes d'immunoglobuline endogenes et produire des anticorps d'idiotype humains transgeniques
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
TW201124427A (en) * 2009-10-15 2011-07-16 Abbott Lab IL-1 binding proteins
WO2011119484A1 (fr) * 2010-03-23 2011-09-29 Iogenetics, Llc Procédés bioinformatiques pour déterminer la liaison de peptides
CA2805653A1 (fr) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anticorps specifiques anti-heterodimere il-23
JP5820688B2 (ja) 2011-03-23 2015-11-24 株式会社Kri 多糖類の溶解に用いられる溶媒ならびに該溶媒を用いた成形体および多糖類誘導体の製造方法
BR112014003999A2 (pt) 2011-08-23 2017-06-13 Roche Glycart Ag anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp
WO2013059885A2 (fr) * 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Produits de recombinaison de polypeptide et utilisations de ceux-ci
JP6499087B2 (ja) 2013-02-26 2019-04-10 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2963057A1 (fr) 2014-07-02 2016-01-06 Calypso Biotech SA Anticorps pour IL-15
CN108064236B (zh) 2015-03-31 2021-12-10 免疫医疗有限公司 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法
CN109311972A (zh) * 2016-06-15 2019-02-05 美国安进公司 用于治疗乳糜泻、非乳糜泻麸质敏感和难治性乳糜泻的方法和组合物
BR112019007281A2 (pt) 2016-10-14 2019-07-09 Xencor Inc proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
RS66900B1 (sr) 2016-12-21 2025-07-31 Cephalon Llc Antitela koja se specifično vezuju za humani il-15 i njihova upotreba

Also Published As

Publication number Publication date
EP3558369A4 (fr) 2020-09-09
BR112019012570A8 (pt) 2023-01-24
AR110414A1 (es) 2019-03-27
PT3558369T (pt) 2025-05-06
PH12019501453A1 (en) 2020-06-15
US20220127352A1 (en) 2022-04-28
EA201991514A1 (ru) 2019-12-30
EP4585261A3 (fr) 2025-08-13
MD3558369T2 (ro) 2025-08-31
BR112019012570A2 (pt) 2019-11-26
ZA201903848B (en) 2023-02-22
MA47130A (fr) 2019-10-30
ES3026508T3 (en) 2025-06-11
MX2019007357A (es) 2019-09-05
EP3558369B1 (fr) 2025-03-26
KR20190097094A (ko) 2019-08-20
LT3558369T (lt) 2025-07-25
JP2020501583A (ja) 2020-01-23
DK3558369T3 (da) 2025-05-19
IL267113A (en) 2019-08-29
IL267113B2 (en) 2024-09-01
CN110234349B (zh) 2024-03-22
WO2018119246A1 (fr) 2018-06-28
US12410247B2 (en) 2025-09-09
UA126284C2 (uk) 2022-09-14
EP4585261A2 (fr) 2025-07-16
US11267883B2 (en) 2022-03-08
HRP20250482T1 (hr) 2025-06-20
FI3558369T3 (fi) 2025-05-02
CN110234349A (zh) 2019-09-13
AU2025201185A1 (en) 2025-03-13
HUE071878T2 (hu) 2025-09-28
JP2022176324A (ja) 2022-11-25
US20200270339A1 (en) 2020-08-27
CA3046387A1 (fr) 2018-06-28
MX2023014081A (es) 2023-12-06
SI3558369T1 (sl) 2025-06-30
EP3558369A1 (fr) 2019-10-30
PE20191497A1 (es) 2019-10-21
AU2017382850A1 (en) 2019-07-04
CL2019001729A1 (es) 2019-09-13
KR102706743B1 (ko) 2024-09-19
KR20230135691A (ko) 2023-09-25
AU2017382850B2 (en) 2024-11-21
JP7155126B2 (ja) 2022-10-18
PL3558369T3 (pl) 2025-06-23
RS66900B1 (sr) 2025-07-31
IL267113B1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
EA201991514A1 (ru) Антитела, которые специфически связываются с ил-15, и их применение
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
MA39313B1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
SG10201914119TA (en) Anti-b7-h3 antibodies and antibody drug conjugates
WO2018229236A3 (fr) Compositions comprenant des souches bactériennes
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA64193B1 (fr) Anticorps bispécifiques se liant aux dll3 et cd3
EA201491827A1 (ru) Антитела против hla-b*27 и их применение
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA53356A (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MA34461B1 (fr) Anticorps anti-peptide beta-amyloide n3pgiu et leurs utilisations
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA20150232A1 (fr) Protéines de fusion de l'interleukine-10 et leurs utilisations
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MA31904B1 (fr) Anticorps bispecifiques bivalents
MA44665B1 (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
MA38485A1 (fr) Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe
MA43088B1 (fr) Anticorps anti-il-17c
MA38369B1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
EP3878867A4 (fr) Anticorps se liant à l'il-1 ? humaine, son procédé de préparation et son utilisation